Risk of death and cardiovascular outcomes with thiazolidinediones: A study with the general practice research database and secondary care data

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Gallagher, Arlene M ^a,b   Smeeth, Liam ^c   Seabroke, Suzie ^a   Leufkens, Hubert G M ^b   van Staa, Tjeerd P ^a,b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA BASE; DEATH; DEATH CERTIFICATE; FEMALE; GENERAL PRACTICE; HEALTH CARE SYSTEM; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL HISTORY; MORTALITY; PRIMARY HEALTH CARE; RISK FACTOR; SIDE EFFECT; SMOKING; STROKE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DIABETES MELLITUS; FACTUAL DATABASE; MIDDLE AGED; RISK; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; RISK; STROKE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 82555175836     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028157     Document Type: Article

References (41)

1. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
2. Nissen SE, Wolski K, (2010) Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med Jun 28 [Epub ahead of print].
3. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE, (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188.
4. FDA website. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf. Accessed 2011 January 14.
5. Lago RM, Singh PP, Nesto RW, (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370: 1129-1136.
6. van Staa TP, Leufkens HG, Zhang B, Smeeth L, (2009) A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med 6: e1000194.
7. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT, (2004) Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: A retrospective data analysis. Clinical Therapeutics 26: 1400-1410.
8. Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM, (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22: 986-993.
9. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, et al. (2005) Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111: 583-590.
10. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD, (2007) The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 16: 504-512.
11. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, et al. (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Safety 16: 1065-1071.
12. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, et al. (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298: 2634-2643.
13. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM, (2007) Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Safety 16: 711-725.
14. Koro CE, Fu Q, Stender M, (2008) An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Safety 17: 989-996.
15. Margolis DJ, Hoffstad O, Strom BL, (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Safety 17: 753-759.
16. Walker AM, Koro CE, Landon J, (2008) Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Safety 17: 760-768.
17. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH, (2008) Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168: 2368-2375.
18. Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, et al. (2009) Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLOS One 4: e 6080.
19. Dore DD, Trivedi AN, Mor V, Lapane KL, (2009) Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy 29: 775-783.
20. Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, et al. (2009) Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: A time-updated propensity analysis. Pharmacoepidemiol Drug Safety 18: 437-447.
21. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, et al. (2009) Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: A retrospective cohort study of over 473,000 patients using the national health insurance database in Taiwan. Drug Safety 32: 675-690.
22. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, et al. (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. BMJ 339: b2942.
23. Shaya FT, Lu Z, Sohn K, Weir MR, (2009) Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. P&T 34: 490-501.
24. Stockl KM, Le L, Zhang S, Harada AS, (2009) Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Pharmacoepidemiol Drug Safety 18: 166-174.
25. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, et al. (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ 339: b4731.
26. Vanasse A, Carpentier AC, Courteau J, Asghari S, (2009) Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diabetes & Vascular Disease Research 6: 87-93.
27. Ziyadeh N, McAfee AT, Koro C, Landon J, Chan KA, (2009) The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database. Clinical Therapeutics 31: 2665-2677.
28. Bilik D, McEwen LN, Brown MB, Selby JV, Karter AJ, et al. (2010) Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiol Drug Safety 19: 715-721.
29. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, et al. (2010) Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 3: 538-545.
30. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, et al. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly patients with rosiglitazone or pioglitazone. JAMA 304: 411-418.
31. Azoulay L, Schneider-Lindner V, Dell'aniello S, Filion KB, Suissa S, (2010) Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Safety 19: 343-350.
32. Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, et al. (2010) Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 33: 526-531.
33. Parkinson J, Davis S, van Staa TP, (2007) The General Practice Research (GPRD) Database: Now and the Future. In: Mann R, editors. Pharmacovigilance pp. 341-348.
34. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ, (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69: 4-14.
35. Ramlau-Hansen H, (1983) Smoothing counting process intensities by means of kernel functional, Ann Statist 11: 453-466.
36. Lash TL, Fox MP, Fink AK, Applying quantitative bias analysis to epidemiologic data. Springer Dordrecht Heidelberg London New York.
37. Loke YK, Kwok CS, Singh S, (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342: d1309 doi:10.1136/bmj.d1309.
38. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, et al. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-2135.
39. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
40. GlaxoSmithKline website. Available: http://www.gsk.com/avandia/GSK-Scientific-Overview-of-Avandia-Data.pdf. Accessed 2010 October 18.
41. de Vries F, de Vries CS, Cooper C, Leufkens HGM, van Staa TP, (2006) Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 35: 1301-1308.